Sunrise Technologies International, Inc. to Provide 1Q, 2001 Guidance And Release Year 2000 Results April 6th

Apr 05, 2001, 01:00 ET from Sunrise Technologies International, Inc.

    FREMONT, Calif., April 5 /PRNewswire/ --
 Sunrise Technologies International, Inc. (Nasdaq:   SNRS) -- today announced
 that it will release its 4th quarter 2000 and its year 2000 results on Friday
 morning, April 6, 2001.
     The Company will also give guidance on 1st quarter 2001 revenue at that
 time.  A conference call will be held at 8:00 a.m. Pacific Daylight Time and
 can be heard over the internet @ v-call.com.
     Sunrise Technologies International, Inc. is a refractive surgery company
 based in Fremont, California, that is developing holmium:YAG laser-based
 systems that utilize a patented process for shrinking collagen developed by
 Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic refractive
 conditions.
     The U.S. Food and Drug Administration approved the Company's HYPERION(TM)
 LTK System on June 30, 2000 for the temporary reduction of hyperopia in
 patients with +0.75 to +2.50 diopters of MRSE with less than or equal to
 +/- 0.75 diopters of astigmatism, who are 40 years of age or older with
 documented stability of refraction for the prior 6 months, as demonstrated by
 a change of less than or equal to 0.50D in spherical and cylindrical
 components of the manifest refraction.  The magnitude of correction with this
 treatment diminishes over time, with some patients retaining some or all of
 their refractive correction.  New labeling says that, based upon existing
 information for the clinical parameters used in the U.S. clinical trial, the
 Company's model for the average longevity for the procedure indicates that
 some of the effect lasts 10 years and beyond, and that age related drift
 towards hyperopia contributes to the loss of effect after the initial two
 years.  Nomograms that are already in use outside of the U.S. treat up to
 5.625 diopters of hyperopia and the effect can last longer than a patient's
 lifetime.
     Except for historical information, this news release contains certain
 forward-looking statements that involve risk and uncertainties, which may
 cause actual results to differ materially from the statements made including
 market potential, regulatory clearances, business growth, and other risks
 listed from time to time in the Company's Securities and Exchange Commission
 (SEC) filings.  These forward-looking statements represent the Company's
 judgment, as of the date of this release, and the Company disclaims any intent
 or obligation to update these forward-looking statements.
     Internet users can access Sunrise's World Wide Web site at
 http://www.sunrise-tech.com .
 
 

SOURCE Sunrise Technologies International, Inc.
    FREMONT, Calif., April 5 /PRNewswire/ --
 Sunrise Technologies International, Inc. (Nasdaq:   SNRS) -- today announced
 that it will release its 4th quarter 2000 and its year 2000 results on Friday
 morning, April 6, 2001.
     The Company will also give guidance on 1st quarter 2001 revenue at that
 time.  A conference call will be held at 8:00 a.m. Pacific Daylight Time and
 can be heard over the internet @ v-call.com.
     Sunrise Technologies International, Inc. is a refractive surgery company
 based in Fremont, California, that is developing holmium:YAG laser-based
 systems that utilize a patented process for shrinking collagen developed by
 Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic refractive
 conditions.
     The U.S. Food and Drug Administration approved the Company's HYPERION(TM)
 LTK System on June 30, 2000 for the temporary reduction of hyperopia in
 patients with +0.75 to +2.50 diopters of MRSE with less than or equal to
 +/- 0.75 diopters of astigmatism, who are 40 years of age or older with
 documented stability of refraction for the prior 6 months, as demonstrated by
 a change of less than or equal to 0.50D in spherical and cylindrical
 components of the manifest refraction.  The magnitude of correction with this
 treatment diminishes over time, with some patients retaining some or all of
 their refractive correction.  New labeling says that, based upon existing
 information for the clinical parameters used in the U.S. clinical trial, the
 Company's model for the average longevity for the procedure indicates that
 some of the effect lasts 10 years and beyond, and that age related drift
 towards hyperopia contributes to the loss of effect after the initial two
 years.  Nomograms that are already in use outside of the U.S. treat up to
 5.625 diopters of hyperopia and the effect can last longer than a patient's
 lifetime.
     Except for historical information, this news release contains certain
 forward-looking statements that involve risk and uncertainties, which may
 cause actual results to differ materially from the statements made including
 market potential, regulatory clearances, business growth, and other risks
 listed from time to time in the Company's Securities and Exchange Commission
 (SEC) filings.  These forward-looking statements represent the Company's
 judgment, as of the date of this release, and the Company disclaims any intent
 or obligation to update these forward-looking statements.
     Internet users can access Sunrise's World Wide Web site at
 http://www.sunrise-tech.com .
 
 SOURCE  Sunrise Technologies International, Inc.